APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tofacitinib Citrate Extended-Release Tablets

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Tofacitinib Citrate Extended-Release Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025184 pages

Choose your research edition.

Industry ResearchTofacitinib Citrate Extended-Release Tablets Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Tofacitinib Citrate Extended-Release Tablets Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Tofacitinib Citrate Extended-Release Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tofacitinib Citrate Extended-Release Tablets Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Tofacitinib Citrate Extended-Release Tablets Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Tofacitinib Citrate Extended-Release Tablets market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Tofacitinib Citrate Extended-Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tofacitinib Citrate Extended-Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tofacitinib Citrate Extended-Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Tofacitinib Citrate Extended-Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Tofacitinib Citrate Extended-Release Tablets include Yichang Humanwell Pharmaceutical, Sichuan Kelun Pharmaceutical, CSPC Ouyi Pharmaceutical, Qilu Pharmaceutical, Lepu Pharmaceutical, Sino Therapeutics, Zydus and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Tofacitinib Citrate Extended-Release Tablets market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tofacitinib Citrate Extended-Release Tablets and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tofacitinib Citrate Extended-Release Tablets sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Tofacitinib Citrate Extended-Release Tablets market size, projected growth trends, production technologies, key applications, and end-use industries.

Tofacitinib Citrate Extended-Release Tablets Segment by Company

Yichang Humanwell Pharmaceutical

Sichuan Kelun Pharmaceutical

CSPC Ouyi Pharmaceutical

Qilu Pharmaceutical

Lepu Pharmaceutical

Sino Therapeutics

Zydus

Pfizer

Tofacitinib Citrate Extended-Release Tablets Segment by Type

11mg per Tablet

22mg per Tablet

Tofacitinib Citrate Extended-Release Tablets Segment by Application

Rheumatoid Arthritis

Psoriatic Arthritis

Ankylosing Spondylitis

Ulcerative Colitis

Other

Tofacitinib Citrate Extended-Release Tablets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tofacitinib Citrate Extended-Release Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tofacitinib Citrate Extended-Release Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tofacitinib Citrate Extended-Release Tablets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Tofacitinib Citrate Extended-Release Tablets market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Tofacitinib Citrate Extended-Release Tablets manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Tofacitinib Citrate Extended-Release Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Tofacitinib Citrate Extended-Release Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Tofacitinib Citrate Extended-Release Tablets Industry Trends Table 2. Tofacitinib Citrate Extended-Release Tablets Industry Drivers Table 3. Tofacitinib Citrate Extended-Release Tablets Industry Opportunities and Challenges Table 4. Tofacitinib Citrate Extended-Release Tablets Industry Restraints Table 5. Global Tofacitinib Citrate Extended-Release Tablets Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Tofacitinib Citrate Extended-Release Tablets Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Manufacturers Table 9. Global Tofacitinib Citrate Extended-Release Tablets Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Tofacitinib Citrate Extended-Release Tablets Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Tofacitinib Citrate Extended-Release Tablets Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Tofacitinib Citrate Extended-Release Tablets Manufacturers, Product Type & Application Table 13. Global Tofacitinib Citrate Extended-Release Tablets Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Tofacitinib Citrate Extended-Release Tablets by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 11mg per Tablet Table 17. Major Manufacturers of 22mg per Tablet Table 18. Global Tofacitinib Citrate Extended-Release Tablets Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021-2026) & (K Units) Table 20. Global Tofacitinib Citrate Extended-Release Tablets Sales by Type (2027-2032) & (K Units) Table 21. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Type (2021-2026) Table 22. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Type (2027-2032) Table 23. Global Tofacitinib Citrate Extended-Release Tablets Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2021-2026) & (K Units) Table 25. Global Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2027-2032) & (K Units) Table 26. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Type (2021-2026) Table 27. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Rheumatoid Arthritis Table 29. Major Manufacturers of Psoriatic Arthritis Table 30. Major Manufacturers of Ankylosing Spondylitis Table 31. Major Manufacturers of Ulcerative Colitis Table 32. Major Manufacturers of Other Table 33. Global Tofacitinib Citrate Extended-Release Tablets Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021-2026) & (K Units) Table 35. Global Tofacitinib Citrate Extended-Release Tablets Sales by Application (2027-2032) & (K Units) Table 36. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Application (2021-2026) Table 37. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Application (2027-2032) Table 38. Global Tofacitinib Citrate Extended-Release Tablets Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2021-2026) & (K Units) Table 40. Global Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2027-2032) & (K Units) Table 41. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Application (2021-2026) Table 42. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Application (2027-2032) Table 43. Global Tofacitinib Citrate Extended-Release Tablets Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Tofacitinib Citrate Extended-Release Tablets Sales by Region (2021-2026) & (K Units) Table 45. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Region (2021-2026) Table 46. Global Tofacitinib Citrate Extended-Release Tablets Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Tofacitinib Citrate Extended-Release Tablets Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Tofacitinib Citrate Extended-Release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2026) & (K Units) Table 50. North America Tofacitinib Citrate Extended-Release Tablets Sales by Country (2027-2032) & (K Units) Table 51. Europe Tofacitinib Citrate Extended-Release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2026) & (K Units) Table 53. Europe Tofacitinib Citrate Extended-Release Tablets Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Tofacitinib Citrate Extended-Release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Tofacitinib Citrate Extended-Release Tablets Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Sales by Country (2027-2032) & (K Units) Table 60. Global Tofacitinib Citrate Extended-Release Tablets Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Region (2021-2026) Table 64. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Region (2027-2032) Table 65. Yichang Humanwell Pharmaceutical Company Information Table 66. Yichang Humanwell Pharmaceutical Business Overview Table 67. Yichang Humanwell Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Yichang Humanwell Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio Table 69. Yichang Humanwell Pharmaceutical Recent Development Table 70. Sichuan Kelun Pharmaceutical Company Information Table 71. Sichuan Kelun Pharmaceutical Business Overview Table 72. Sichuan Kelun Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Sichuan Kelun Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio Table 74. Sichuan Kelun Pharmaceutical Recent Development Table 75. CSPC Ouyi Pharmaceutical Company Information Table 76. CSPC Ouyi Pharmaceutical Business Overview Table 77. CSPC Ouyi Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. CSPC Ouyi Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio Table 79. CSPC Ouyi Pharmaceutical Recent Development Table 80. Qilu Pharmaceutical Company Information Table 81. Qilu Pharmaceutical Business Overview Table 82. Qilu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Qilu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio Table 84. Qilu Pharmaceutical Recent Development Table 85. Lepu Pharmaceutical Company Information Table 86. Lepu Pharmaceutical Business Overview Table 87. Lepu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Lepu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio Table 89. Lepu Pharmaceutical Recent Development Table 90. Sino Therapeutics Company Information Table 91. Sino Therapeutics Business Overview Table 92. Sino Therapeutics Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Sino Therapeutics Tofacitinib Citrate Extended-Release Tablets Product Portfolio Table 94. Sino Therapeutics Recent Development Table 95. Zydus Company Information Table 96. Zydus Business Overview Table 97. Zydus Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Zydus Tofacitinib Citrate Extended-Release Tablets Product Portfolio Table 99. Zydus Recent Development Table 100. Pfizer Company Information Table 101. Pfizer Business Overview Table 102. Pfizer Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Pfizer Tofacitinib Citrate Extended-Release Tablets Product Portfolio Table 104. Pfizer Recent Development Table 105. Key Raw Materials Table 106. Raw Materials Key Suppliers Table 107. Tofacitinib Citrate Extended-Release Tablets Distributors List Table 108. Tofacitinib Citrate Extended-Release Tablets Customers List Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Tofacitinib Citrate Extended-Release Tablets Product Image Figure 2. Global Tofacitinib Citrate Extended-Release Tablets Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tofacitinib Citrate Extended-Release Tablets Market Size (2021-2032) & (US$ Million) Figure 4. Global Tofacitinib Citrate Extended-Release Tablets Sales (2021-2032) & (K Units) Figure 5. Global Tofacitinib Citrate Extended-Release Tablets Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Tofacitinib Citrate Extended-Release Tablets Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 11mg per Tablet Image Figure 9. 22mg per Tablet Image Figure 10. Global Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Type (2021-2032) Figure 13. Global Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Type (2021-2032) Figure 16. Rheumatoid Arthritis Image Figure 17. Psoriatic Arthritis Image Figure 18. Ankylosing Spondylitis Image Figure 19. Ulcerative Colitis Image Figure 20. Other Image Figure 21. Global Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Application (2021-2032) Figure 24. Global Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Application (2021-2032) Figure 27. North America Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Country (2021-2032) Figure 29. U.S. Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Country (2021-2032) Figure 34. Germany Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Country (2021-2032) Figure 41. China Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Country (2021-2032) Figure 49. Brazil Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Tofacitinib Citrate Extended-Release Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Tofacitinib Citrate Extended-Release Tablets Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Figure 60. North America Tofacitinib Citrate Extended-Release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Figure 62. Europe Tofacitinib Citrate Extended-Release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Tofacitinib Citrate Extended-Release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Tofacitinib Citrate Extended-Release Tablets Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Tofacitinib Citrate Extended-Release Tablets Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • 11mg per Tablet
  • 22mg per Tablet
Applications
  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Ulcerative Colitis
  • Other
Companies covered
  • Yichang Humanwell Pharmaceutical
  • Sichuan Kelun Pharmaceutical
  • CSPC Ouyi Pharmaceutical
  • Qilu Pharmaceutical
  • Lepu Pharmaceutical
  • Sino Therapeutics
  • Zydus
  • Pfizer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Tofacitinib Citrate Extended-Release Tablets Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Tofacitinib Citrate Extended-Release Tablets Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Tofacitinib Citrate Extended-Release Tablets Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Tofacitinib Citrate Extended-Release Tablets Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Tofacitinib Citrate Extended-Release Tablets Market Dynamics
  1. 2.1 Tofacitinib Citrate Extended-Release Tablets Industry Trends
  2. 2.2 Tofacitinib Citrate Extended-Release Tablets Industry Drivers
  3. 2.3 Tofacitinib Citrate Extended-Release Tablets Industry Opportunities and Challenges
  4. 2.4 Tofacitinib Citrate Extended-Release Tablets Industry Restraints
3 Tofacitinib Citrate Extended-Release Tablets Market by Manufacturers
  1. 3.1 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Tofacitinib Citrate Extended-Release Tablets Sales by Manufacturers (2021-2026)
  3. 3.3 Global Tofacitinib Citrate Extended-Release Tablets Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Tofacitinib Citrate Extended-Release Tablets Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Tofacitinib Citrate Extended-Release Tablets Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Tofacitinib Citrate Extended-Release Tablets Manufacturers, Product Type & Application
  7. 3.7 Global Tofacitinib Citrate Extended-Release Tablets Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Tofacitinib Citrate Extended-Release Tablets Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Tofacitinib Citrate Extended-Release Tablets Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Tofacitinib Citrate Extended-Release Tablets Tier 1, Tier 2, and Tier 3
4 Tofacitinib Citrate Extended-Release Tablets Market by Type
  1. 4.1 Tofacitinib Citrate Extended-Release Tablets Type Introduction
  2. 4.1.1 11mg per Tablet
  3. 4.1.2 22mg per Tablet
  4. 4.2 Global Tofacitinib Citrate Extended-Release Tablets Sales by Type
  5. 4.2.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021-2032)
  7. 4.2.3 Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Type (2021-2032)
  8. 4.3 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Type
  9. 4.3.1 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2021-2032)
  11. 4.3.3 Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Type (2021-2032)
5 Tofacitinib Citrate Extended-Release Tablets Market by Application
  1. 5.1 Tofacitinib Citrate Extended-Release Tablets Application Introduction
  2. 5.1.1 Rheumatoid Arthritis
  3. 5.1.2 Psoriatic Arthritis
  4. 5.1.3 Ankylosing Spondylitis
  5. 5.1.4 Ulcerative Colitis
  6. 5.1.5 Other
  7. 5.2 Global Tofacitinib Citrate Extended-Release Tablets Sales by Application
  8. 5.2.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021-2032)
  10. 5.2.3 Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Application (2021-2032)
  11. 5.3 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Application
  12. 5.3.1 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2021-2032)
  14. 5.3.3 Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Application (2021-2032)
6 Global Tofacitinib Citrate Extended-Release Tablets Sales by Region
  1. 6.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tofacitinib Citrate Extended-Release Tablets Sales by Region (2021-2032)
  3. 6.2.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Region (2021-2026)
  4. 6.2.2 Global Tofacitinib Citrate Extended-Release Tablets Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Tofacitinib Citrate Extended-Release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Tofacitinib Citrate Extended-Release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Tofacitinib Citrate Extended-Release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region
  1. 7.1 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region
  2. 7.1.1 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region (2021-2026)
  4. 7.1.3 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region (2027-2032)
  5. 7.1.4 Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032)
  8. 7.2.2 North America Tofacitinib Citrate Extended-Release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032)
  11. 7.3.2 Europe Tofacitinib Citrate Extended-Release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Tofacitinib Citrate Extended-Release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Yichang Humanwell Pharmaceutical
  2. 8.1.1 Yichang Humanwell Pharmaceutical Company Information
  3. 8.1.2 Yichang Humanwell Pharmaceutical Business Overview
  4. 8.1.3 Yichang Humanwell Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Yichang Humanwell Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
  6. 8.1.5 Yichang Humanwell Pharmaceutical Recent Developments
  7. 8.2 Sichuan Kelun Pharmaceutical
  8. 8.2.1 Sichuan Kelun Pharmaceutical Company Information
  9. 8.2.2 Sichuan Kelun Pharmaceutical Business Overview
  10. 8.2.3 Sichuan Kelun Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sichuan Kelun Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
  12. 8.2.5 Sichuan Kelun Pharmaceutical Recent Developments
  13. 8.3 CSPC Ouyi Pharmaceutical
  14. 8.3.1 CSPC Ouyi Pharmaceutical Company Information
  15. 8.3.2 CSPC Ouyi Pharmaceutical Business Overview
  16. 8.3.3 CSPC Ouyi Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 CSPC Ouyi Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
  18. 8.3.5 CSPC Ouyi Pharmaceutical Recent Developments
  19. 8.4 Qilu Pharmaceutical
  20. 8.4.1 Qilu Pharmaceutical Company Information
  21. 8.4.2 Qilu Pharmaceutical Business Overview
  22. 8.4.3 Qilu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Qilu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
  24. 8.4.5 Qilu Pharmaceutical Recent Developments
  25. 8.5 Lepu Pharmaceutical
  26. 8.5.1 Lepu Pharmaceutical Company Information
  27. 8.5.2 Lepu Pharmaceutical Business Overview
  28. 8.5.3 Lepu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Lepu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
  30. 8.5.5 Lepu Pharmaceutical Recent Developments
  31. 8.6 Sino Therapeutics
  32. 8.6.1 Sino Therapeutics Company Information
  33. 8.6.2 Sino Therapeutics Business Overview
  34. 8.6.3 Sino Therapeutics Tofacitinib Citrate Extended-Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sino Therapeutics Tofacitinib Citrate Extended-Release Tablets Product Portfolio
  36. 8.6.5 Sino Therapeutics Recent Developments
  37. 8.7 Zydus
  38. 8.7.1 Zydus Company Information
  39. 8.7.2 Zydus Business Overview
  40. 8.7.3 Zydus Tofacitinib Citrate Extended-Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Zydus Tofacitinib Citrate Extended-Release Tablets Product Portfolio
  42. 8.7.5 Zydus Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Tofacitinib Citrate Extended-Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Tofacitinib Citrate Extended-Release Tablets Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Tofacitinib Citrate Extended-Release Tablets Value Chain Analysis
  2. 9.1.1 Tofacitinib Citrate Extended-Release Tablets Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Tofacitinib Citrate Extended-Release Tablets Production Mode & Process
  6. 9.2 Tofacitinib Citrate Extended-Release Tablets Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Tofacitinib Citrate Extended-Release Tablets Distributors
  9. 9.2.3 Tofacitinib Citrate Extended-Release Tablets Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst